Tramadol to Improve Its Detection in Biological Matrices in Anti-doping Controls
Status:
Completed
Trial end date:
2023-10-17
Target enrollment:
Participant gender:
Summary
Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg
for extensive and poor metabolizers will be administered with the objective to evaluate urine
and blood concentrations in healthy volunteers.